Abstract: A battery restraint apparatus includes a restraint structure, the restraint structure including a restraint frame, a cushion pad, and a positioning column. The restraint frame is provided with a positioning hole; the cushion pad is arranged on the restraint frame; and the positioning column is arranged on the cushion pad and is inserted and fitted into the positioning hole. The positioning hole is formed in the restraint frame, and the positioning column to be inserted and fitted into the positioning hole is provided on the cushion pad, so that the positioning of the cushion pad on the restraint frame can be achieved by inserting the positioning column on the cushion pad into the positioning hole.

Abstract: The present invention provides formulations of (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, and methods of making and using the same.

Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Abstract: This application relates to the field of battery manufacturing technologies and provides a battery formation and grading device including: a box having an accommodating space; a temperature control apparatus, provided on the box, including a semiconductor cooling sheet, where two opposite sides of the semiconductor cooling sheet are configured as a cooling surface and a heating surface, the cooling surface being arranged facing the inside of the box and the heating surface being arranged facing the outside of the box. The technical solution of this application improves the efficiency of temperature control inside the battery formation and grading device and reduces the cost of temperature control.

Abstract: The present invention provides formulations of (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, and methods of making and using the same.

Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Abstract: An electrode plate molding device is disclosed, including a conveying mechanism, a cutting mechanism, a first detection mechanism, and a deviation rectification mechanism. The conveying mechanism is configured to convey an electrode plate strip. The cutting mechanism is arranged downstream of the conveying mechanism along a conveying direction of the electrode plate strip. The cutting mechanism is configured to cut the electrode plate strip to form an electrode plate. The first detection mechanism is located upstream of the cutting mechanism along the conveying direction. The first detection mechanism is configured to detect a location of the electrode plate strip along a width direction of the electrode plate strip. The deviation rectification mechanism adjusts relative locations of the electrode plate strip and the cutting mechanism along the width direction in response to a detection result of the first detection mechanism.

Abstract: This application relates to the field of battery manufacturing technologies and provides a battery formation and grading device including: a box having an accommodating space; a temperature control apparatus, provided on the box, including a semiconductor cooling sheet, where two opposite sides of the semiconductor cooling sheet are configured as a cooling surface and a heating surface, the cooling surface being arranged facing the inside of the box and the heating surface being arranged facing the outside of the box. The technical solution of this application improves the efficiency of temperature control inside the battery formation and grading device and reduces the cost of temperature control.

Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Abstract: The present invention provides formulations of (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, and methods of making and using the same.

Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.

Abstract: Provided are a test assembly and a test tooling, including: interfaces, where one end of the interface is configured to connect a device under test, and the interfaces include a first interface and a second interface; a first three-way valve, where the first three-way valve includes a first cut-in valve, a first vent valve, and a first test valve, another end of the first interface is connected to the first cut-in valve, and the first vent valve lets in atmospheric air and is able to open and close; a second three-way valve, where the second three-way valve includes a second cut-in valve, a second vent valve, and a second test valve, another end of the second interface is connected to the second cut-in valve, and the second vent valve lets in atmospheric air and is able to open and close; and a manifold.

Abstract: For in mold spraying, a double-inclined mixing nozzle is connected obliquely and fixedly with a side surface of a third half-mold through a lateral sealing structure and connected with a side surface of a first half-mold in an inclined and sealing manner, side faces of a first half-mold and the third half-mold are respectively provided with installation inclined surfaces. A lateral sealing structure includes a mounting plate and a sealing member. The sealing member is sleeved on the double-inclined mixing nozzle and is in transition fit with the double-inclined mixing nozzle and the mounting plate respectively. A butt sealing groove provided on the installation inclined surface of the first half-mold and is in sealing fit with the mounting plate.

Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Abstract: Provided are a test assembly and a test tooling, including: interfaces, where one end of the interface is configured to connect a device under test, and the interfaces include a first interface and a second interface; a first three-way valve, where the first three-way valve includes a first cut-in valve, a first vent valve, and a first test valve, another end of the first interface is connected to the first cut-in valve, and the first vent valve lets in atmospheric air and is able to open and close; a second three-way valve, where the second three-way valve includes a second cut-in valve, a second vent valve, and a second test valve, another end of the second interface is connected to the second cut-in valve, and the second vent valve lets in atmospheric air and is able to open and close; and a manifold.

Abstract: For in mold spraying, a double-inclined mixing nozzle is connected obliquely and fixedly with a side surface of a third half-mold through a lateral sealing structure and connected with a side surface of a first half-mold in an inclined and sealing manner, side faces of a first half-mold and the third half-mold are respectively provided with installation inclined surfaces. A lateral sealing structure includes a mounting plate and a sealing member. The sealing member is sleeved on the double-inclined mixing nozzle and is in transition fit with the double-inclined mixing nozzle and the mounting plate respectively. A butt sealing groove provided on the installation inclined surface of the first half-mold and is in sealing fit with the mounting plate.

Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.

Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.

Abstract: For processing cost reduction and improvement of efficiency, a no-mold-runner multi-nozzle device, comprising: an injection machine, a multi-nozzle component, a front template, and a no-mold-runner. The multi-nozzle component includes a plurality of nozzles, which is connected to the injection machine. The injection machine is used to inject a mixture of molding material and supercritical fluid into multiple nozzles. The front template is provided with a plurality of first passage holes. The no-mold-runner is provided with a mold cavity and a plurality of second passage holes communicating with the mold cavity. The nozzle correspondingly passes through a plurality of first passage holes and second passage holes and is installed in cooperation. By controlling the opening or closing of the nozzle, the mixed material of the molding material and the supercritical fluid enters the mold cavity or stops entering the mold cavity.

Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.